Condensed Consolidated Statements of Earnings (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net Sales	$ 1,831.0	$ 1,663.2
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization	$ 500.8	$ 500.0
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Intangible asset amortization	$ 133.4	$ 130.8
Research and development	110.4	96.9
Selling, general and administrative	715.9	684.5
Restructuring and other cost reduction initiatives	41.8	43.9
Quality remediation		6.5
Acquisition, integration, divestiture and related	1.3	2.2
Operating expenses	1,503.7	1,464.8
Operating Profit	327.3	198.4
Other income (expense), net	7.7	(56.1)
Interest expense, net	(48.2)	(41.1)
Earnings from continuing operations before income taxes	286.8	101.2
Provision for income taxes from continuing operations	54.1	28.0
Net Earnings from continuing operations	232.8	73.2
Less: Net earnings attributable to noncontrolling interest	0.2	0.2
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc.	232.5	73.0
Loss from discontinued operations, net of taxes		(58.8)
Net Earnings of Zimmer Biomet Holdings, Inc.	$ 232.5	$ 14.2
Earnings Per Common Share - Basic
Earnings from continuing operations	$ 1.11	$ 0.35
Loss from discontinued operations		(0.28)
Net Earnings Per Common Share - Basic	1.11	0.07
Earnings Per Common Share - Diluted
Earnings from continuing operations	1.11	0.35
Loss from discontinued operations		(0.28)
Net Earnings Per Common Share - Diluted	$ 1.11	$ 0.07
Weighted Average Common Shares Outstanding
Basic	209.4	209.2
Diluted	210.4	210.1